Bio-Path Holdings Files 8-K
Ticker: BPTH · Form: 8-K · Filed: Apr 2, 2024 · CIK: 1133818
| Field | Detail |
|---|---|
| Company | Bio-Path Holdings Inc (BPTH) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: BPTH
TL;DR
BPTH filed a routine 8-K, no new news.
AI Summary
Bio-Path Holdings, Inc. filed an 8-K on April 2, 2024, to report information under Regulation FD and to file financial statements and exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this form.
Why It Matters
This 8-K filing indicates Bio-Path Holdings is fulfilling its regulatory disclosure obligations, but it does not announce new material events or financial results.
Risk Assessment
Risk Level: low — The filing is a standard regulatory disclosure and does not contain any new material information that would impact the company's risk profile.
Key Players & Entities
- BIO-PATH HOLDINGS, INC. (company) — Registrant
- 0001558370-24-004601 (filing_id) — Accession Number
- April 2, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 77401 (zip_code) — Business address zip code
FAQ
What is the primary purpose of this 8-K filing for Bio-Path Holdings, Inc.?
The primary purpose is to report information under Regulation FD Disclosure and to file Financial Statements and Exhibits, as indicated in the filing.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on April 2, 2024.
What is Bio-Path Holdings, Inc.'s state of incorporation?
Bio-Path Holdings, Inc. is incorporated in Delaware.
What is the company's principal executive office address?
The address of the principal executive offices is 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401.
Does this filing announce any specific new business developments or financial results?
No, this filing primarily serves as a current report for regulatory disclosure and filing of exhibits, without announcing specific new business developments or financial results.
Filing Stats: 429 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2024-04-02 16:10:13
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share BPTH The Nasdaq Capital M
Filing Documents
- bpth-20240402x8k.htm (8-K) — 38KB
- bpth-20240402xex99d1.htm (EX-99.1) — 29KB
- bpth-20240402xex99d1001.jpg (GRAPHIC) — 11KB
- 0001558370-24-004601.txt ( ) — 207KB
- bpth-20240402.xsd (EX-101.SCH) — 3KB
- bpth-20240402_lab.xml (EX-101.LAB) — 16KB
- bpth-20240402_pre.xml (EX-101.PRE) — 10KB
- bpth-20240402x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On April 2, 2024, Bio-Path Holdings, Inc. (the "Company") issued a press release titled, "Bio-Path Holdings Provides 2024 Clinical and Operational Update." A copy of such press release is attached hereto as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press release dated April 2, 2024. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-PATH HOLDINGS, INC. Dated: April 2, 2024 By: /s/ Peter H. Nielsen Peter H. Nielsen President and Chief Executive Officer